

Xuejiao Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1456077/publications.pdf>

Version: 2024-02-01

37
papers

796
citations

516710

16
h-index

526287

27
g-index

39
all docs

39
docs citations

39
times ranked

1207
citing authors

#	ARTICLE	IF	CITATIONS
1	Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy. <i>Theranostics</i> , 2018, 8, 5088-5105.	10.0	104
2	The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 219.	8.6	85
3	CRM1/XPO1 is associated with clinical outcome in glioma and represents a therapeutic target by perturbing multiple core pathways. <i>Journal of Hematology and Oncology</i> , 2016, 9, 108.	17.0	58
4	The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway. <i>Cancer Letters</i> , 2018, 415, 151-163.	7.2	44
5	Piperlongumine is a novel nuclear export inhibitor with potent anticancer activity. <i>Chemico-Biological Interactions</i> , 2015, 237, 66-72.	4.0	37
6	Plumbagin inhibits growth of gliomas in vivo via suppression of FOXM1 expression. <i>Journal of Pharmacological Sciences</i> , 2015, 128, 131-136.	2.5	36
7	High expression of Bruton's tyrosine kinase (BTK) is required for EGFR-induced NF- κ B activation and predicts poor prognosis in human glioma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 132.	8.6	36
8	CRM1 Is a Direct Cellular Target of the Natural Anti-cancer Agent Plumbagin. <i>Journal of Pharmacological Sciences</i> , 2014, 124, 486-493.	2.5	27
9	Overexpression of RASD1 inhibits glioma cell migration/invasion and inactivates the AKT/mTOR signaling pathway. <i>Scientific Reports</i> , 2017, 7, 3202.	3.3	26
10	Novel reversible selective inhibitor of nuclear export shows that CRM1 is a target in colorectal cancer cells. <i>Cancer Biology and Therapy</i> , 2015, 16, 1110-1118.	3.4	25
11	Plumbagin induces growth inhibition of human glioma cells by downregulating the expression and activity of FOXM1. <i>Journal of Neuro-Oncology</i> , 2015, 121, 469-477.	2.9	25
12	Smoothed is a poor prognosis factor and a potential therapeutic target in glioma. <i>Scientific Reports</i> , 2017, 7, 42630.	3.3	24
13	Piperlongumine selectively suppresses ABC-DLBCL through inhibition of NF- κ B p65 subunit nuclear import. <i>Biochemical and Biophysical Research Communications</i> , 2015, 462, 326-331.	2.1	22
14	MALT1 is a potential therapeutic target in glioblastoma and plays a crucial role in EGFR-induced NF- κ B activation. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 7550-7562.	3.6	22
15	GRP78 determines glioblastoma sensitivity to UBA1 inhibition-induced UPR signaling and cell death. <i>Cell Death and Disease</i> , 2021, 12, 733.	6.3	19
16	Hugl-1 inhibits glioma cell growth in intracranial model. <i>Journal of Neuro-Oncology</i> , 2015, 125, 113-121.	2.9	18
17	Effects of ERK1/2 S-nitrosylation on ERK1/2 phosphorylation and cell survival in glioma cells. <i>International Journal of Molecular Medicine</i> , 2018, 41, 1339-1348.	4.0	18
18	Novel reversible selective inhibitor of CRM1 for targeted therapy in ovarian cancer. <i>Journal of Ovarian Research</i> , 2015, 8, 35.	3.0	16

#	ARTICLE	IF	CITATIONS
19	BYSL contributes to tumor growth by cooperating with the mTORC2 complex in gliomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 88-104.	3.0	16
20	MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy. <i>Journal of Translational Medicine</i> , 2018, 16, 267.	4.4	15
21	Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia. <i>Biomedicine and Pharmacotherapy</i> , 2019, 117, 109113.	5.6	13
22	Tautomycetin Induces Apoptosis by Inactivating Akt Through a PP1-Independent Signaling Pathway in Human Breast Cancer Cells. <i>Journal of Pharmacological Sciences</i> , 2013, 121, 17-24.	2.5	12
23	MELK Inhibition Effectively Suppresses Growth of Glioblastoma and Cancer Stem-Like Cells by Blocking AKT and FOXM1 Pathways. <i>Frontiers in Oncology</i> , 2020, 10, 608082.	2.8	12
24	High expression of miR-363 predicts poor prognosis and guides treatment selection in acute myeloid leukemia. <i>Journal of Translational Medicine</i> , 2019, 17, 106.	4.4	10
25	FoxR2 promotes glioma proliferation by suppression of the p27 pathway. <i>Oncotarget</i> , 2017, 8, 56255-56266.	1.8	10
26	CRM1 inhibitor S109 suppresses cell proliferation and induces cell cycle arrest in renal cancer cells. <i>Korean Journal of Physiology and Pharmacology</i> , 2016, 20, 161.	1.2	9
27	Effects of realgar (As ₄ S ₄) on degradation of PML-RARA harboring acquired arsenic-resistance mutations. <i>Annals of Hematology</i> , 2017, 96, 1945-1948.	1.8	7
28	Effects of Long Form of CAPON Overexpression on Glioma Cell Proliferation are Dependent on AKT/mTOR/P53 Signaling. <i>International Journal of Medical Sciences</i> , 2019, 16, 614-622.	2.5	7
29	High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia. <i>Cancer Cell International</i> , 2019, 19, 122.	4.1	6
30	SWAP-70 promotes glioblastoma cellular migration and invasion by regulating the expression of CD44s. <i>Cancer Cell International</i> , 2019, 19, 305.	4.1	6
31	Csnk1a1 inhibition modulates the inflammatory secretome and enhances response to radiotherapy in glioma. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 7395-7406.	3.6	6
32	GRP78 blockade overcomes intrinsic resistance to UBA1 inhibitor TAK-243 in glioblastoma. <i>Cell Death Discovery</i> , 2022, 8, 133.	4.7	6
33	MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF- κ B Activation. <i>Frontiers in Oncology</i> , 2020, 10, 558339.	2.8	5
34	CARMA1 is required for Notch1-induced NF- κ B activation in SIL-TAL1-negative T cell acute lymphoblastic leukemia. <i>Journal of Molecular Medicine</i> , 2021, 99, 1447-1458.	3.9	5
35	Reversible inhibitor of CRM1 sensitizes glioblastoma cells to radiation by blocking the NF- κ B signaling pathway. <i>Cancer Cell International</i> , 2020, 20, 97.	4.1	4
36	MiR-340 Is a Biomarker for Selecting Treatment Between Chemotherapy and Allogeneic Transplantation in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 1058.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Inhibition of chromosomal region maintenance 1 suppresses the migration and invasion of glioma cells via inactivation of the STAT3/MMP2 signaling pathway. Korean Journal of Physiology and Pharmacology, 2020, 24, 193-201.	1.2	2